BACKGROUND: Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including high levels of DNA methylation. METHODS: We retrospectively evaluated 50 t-MN patients (34 MDS and 16 AML) selected among all patients receiving azacitidine (AZA) at 10 Italian Hematology Centers. Patients had developed a t-MN at a median of 6.5 years (range 1.7- 29) after treatment of the primary tumor (hematological neoplasm, 27 patients; solid tumor, 23 patients). RESULTS: The overall response rate was 42% (complete remission: 10 patients, partial remission: 2 and hematological improvement: 8 patients) and was obtained after a median of 3 cycles (range 1-6). Median overall survival (OS) was 21 months (range 1-53.6+) from AZA start. OS was significantly better in patients with less than 20% blasts, in normal karyotype t-AML and when AZA was used as front-line treatment. This was confirmed by the multivariate analysis. CONCLUSIONS: This study reports efficacy of AZA in the largest series of therapy-related MN patients treated with 5-AZA. Our data show that blasts and karyotype maintain their important prognostic role in t-MN also in the azacitidine era.

Fianchi, L., Criscuolo, M., Lunghi, M., Gaidano, G., Breccia, M., Levis, A., Finelli, C., Santini, V., Musto, P., Oliva, E., Leoni, P., Spiriti, A., D'Alo', F., Hohaus, S., Pagano, L., Leone, G., Voso, M. T., Outcome of therapy-related myeloid neoplasms treated with azacitidine, <<JOURNAL OF HEMATOLOGY & ONCOLOGY>>, 2012; 5 (Agosto): 44-44. [doi:10.1186/1756-8722-5-44] [http://hdl.handle.net/10807/29505]

Outcome of therapy-related myeloid neoplasms treated with azacitidine

Fianchi, Luana;Criscuolo, Marianna;D'Alo', Francesco;Hohaus, Stefan;Pagano, Livio;Leone, Giuseppe;Voso, Maria Teresa
2012

Abstract

BACKGROUND: Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including high levels of DNA methylation. METHODS: We retrospectively evaluated 50 t-MN patients (34 MDS and 16 AML) selected among all patients receiving azacitidine (AZA) at 10 Italian Hematology Centers. Patients had developed a t-MN at a median of 6.5 years (range 1.7- 29) after treatment of the primary tumor (hematological neoplasm, 27 patients; solid tumor, 23 patients). RESULTS: The overall response rate was 42% (complete remission: 10 patients, partial remission: 2 and hematological improvement: 8 patients) and was obtained after a median of 3 cycles (range 1-6). Median overall survival (OS) was 21 months (range 1-53.6+) from AZA start. OS was significantly better in patients with less than 20% blasts, in normal karyotype t-AML and when AZA was used as front-line treatment. This was confirmed by the multivariate analysis. CONCLUSIONS: This study reports efficacy of AZA in the largest series of therapy-related MN patients treated with 5-AZA. Our data show that blasts and karyotype maintain their important prognostic role in t-MN also in the azacitidine era.
2012
Inglese
Fianchi, L., Criscuolo, M., Lunghi, M., Gaidano, G., Breccia, M., Levis, A., Finelli, C., Santini, V., Musto, P., Oliva, E., Leoni, P., Spiriti, A., D'Alo', F., Hohaus, S., Pagano, L., Leone, G., Voso, M. T., Outcome of therapy-related myeloid neoplasms treated with azacitidine, <<JOURNAL OF HEMATOLOGY & ONCOLOGY>>, 2012; 5 (Agosto): 44-44. [doi:10.1186/1756-8722-5-44] [http://hdl.handle.net/10807/29505]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/29505
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 43
social impact